188.28 USD
-1.92 (-1.01%)
Overall LGND gets a fundamental rating of 6 out of 10. We evaluated LGND against 191 industry peers in the Pharmaceuticals industry. LGND has an excellent profitability rating, but there are some minor concerns on its financial health. LGND is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make LGND suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year LGND was profitable.
LGND had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: LGND reported negative net income in multiple years.
LGND had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
LGND's Return On Assets of 3.29% is amongst the best of the industry. LGND outperforms 83.25% of its industry peers.
The Return On Equity of LGND (5.11%) is better than 83.25% of its industry peers.
LGND has a better Return On Invested Capital (1.58%) than 78.53% of its industry peers.
The Average Return On Invested Capital over the past 3 years for LGND is significantly below the industry average of 12.85%.
The 3 year average ROIC (1.12%) for LGND is below the current ROIC(1.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROIC | 1.58% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
1.3 Margins
LGND's Profit Margin of 19.34% is amongst the best of the industry. LGND outperforms 90.58% of its industry peers.
LGND's Operating Margin of 11.48% is amongst the best of the industry. LGND outperforms 84.29% of its industry peers.
LGND's Operating Margin has declined in the last couple of years.
LGND has a better Gross Margin (94.27%) than 96.34% of its industry peers.
In the last couple of years the Gross Margin of LGND has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
LGND has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, LGND has more shares outstanding
Compared to 5 years ago, LGND has more shares outstanding
The debt/assets ratio for LGND is higher compared to a year ago.
2.2 Solvency
LGND has an Altman-Z score of 5.64. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of LGND (5.64) is better than 75.92% of its industry peers.
The Debt to FCF ratio of LGND is 14.48, which is on the high side as it means it would take LGND, 14.48 years of fcf income to pay off all of its debts.
LGND has a Debt to FCF ratio of 14.48. This is in the better half of the industry: LGND outperforms 76.96% of its industry peers.
LGND has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LGND (0.47) is worse than 62.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Altman-Z | 5.64 |
ROIC/WACC0.17
WACC9.3%
2.3 Liquidity
LGND has a Current Ratio of 24.69. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 24.69, LGND belongs to the best of the industry, outperforming 93.72% of the companies in the same industry.
LGND has a Quick Ratio of 24.30. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
LGND has a better Quick ratio (24.30) than 92.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.26% over the past year.
The Earnings Per Share has been growing by 13.44% on average over the past years. This is quite good.
Looking at the last year, LGND shows a very strong growth in Revenue. The Revenue has grown by 64.83%.
Measured over the past years, LGND shows a small growth in Revenue. The Revenue has been growing by 6.80% on average per year.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
3.2 Future
Based on estimates for the next years, LGND will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.25% on average per year.
Based on estimates for the next years, LGND will show a very strong growth in Revenue. The Revenue will grow by 21.75% on average per year.
EPS Next Y30.63%
EPS Next 2Y21.4%
EPS Next 3Y19.77%
EPS Next 5Y16.25%
Revenue Next Year53.36%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y21.75%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
LGND is valuated quite expensively with a Price/Earnings ratio of 25.83.
Based on the Price/Earnings ratio, LGND is valued a bit cheaper than the industry average as 78.01% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of LGND to the average of the S&P500 Index (26.77), we can say LGND is valued inline with the index average.
A Price/Forward Earnings ratio of 22.38 indicates a rather expensive valuation of LGND.
LGND's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. LGND is cheaper than 74.87% of the companies in the same industry.
LGND's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.83 | ||
| Fwd PE | 22.38 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than 77.49% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than the industry average as 74.35% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 120.46 | ||
| EV/EBITDA | 47.58 |
4.3 Compensation for Growth
LGND's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of LGND may justify a higher PE ratio.
A more expensive valuation may be justified as LGND's earnings are expected to grow with 19.77% in the coming years.
PEG (NY)0.84
PEG (5Y)1.92
EPS Next 2Y21.4%
EPS Next 3Y19.77%
5. Dividend
5.1 Amount
LGND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:LGND (12/31/2025, 3:49:36 PM)
188.28
-1.92 (-1.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.5%
Inst Owner Change87.96%
Ins Owners1.62%
Ins Owner Change-1.26%
Market Cap3.71B
Revenue(TTM)251.23M
Net Income(TTM)48.58M
Analysts84.62
Price Target248.31 (31.88%)
Short Float %5.7%
Short Ratio5.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)6.72%
PT rev (3m)32.94%
EPS NQ rev (1m)5.26%
EPS NQ rev (3m)-23.81%
EPS NY rev (1m)6.52%
EPS NY rev (3m)6.52%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-11.05%
Revenue NY rev (1m)16.66%
Revenue NY rev (3m)16.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.83 | ||
| Fwd PE | 22.38 | ||
| P/S | 14.75 | ||
| P/FCF | 120.46 | ||
| P/OCF | 116.1 | ||
| P/B | 3.9 | ||
| P/tB | 9.06 | ||
| EV/EBITDA | 47.58 |
EPS(TTM)7.29
EY3.87%
EPS(NY)8.41
Fwd EY4.47%
FCF(TTM)1.56
FCFY0.83%
OCF(TTM)1.62
OCFY0.86%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)0.84
PEG (5Y)1.92
Graham Number88.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROCE | 1.99% | ||
| ROIC | 1.58% | ||
| ROICexc | 2.92% | ||
| ROICexgc | 9.48% | ||
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% | ||
| FCFM | 12.24% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 3.38% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 96.15 | ||
| Cash Conversion | 50.63% | ||
| Profit Quality | 63.32% | ||
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 | ||
| Altman-Z | 5.64 |
F-Score5
WACC9.3%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y30.63%
EPS Next 2Y21.4%
EPS Next 3Y19.77%
EPS Next 5Y16.25%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year53.36%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y21.75%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.59%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A
LIGAND PHARMACEUTICALS / LGND FAQ
What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a fundamental rating of 6 / 10 to LGND.
Can you provide the valuation status for LIGAND PHARMACEUTICALS?
ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
How profitable is LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.
What is the valuation of LIGAND PHARMACEUTICALS based on its PE and PB ratios?
The Price/Earnings (PE) ratio for LIGAND PHARMACEUTICALS (LGND) is 25.83 and the Price/Book (PB) ratio is 3.9.
Can you provide the expected EPS growth for LGND stock?
The Earnings per Share (EPS) of LIGAND PHARMACEUTICALS (LGND) is expected to grow by 30.63% in the next year.